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mplication of Different Cardiac
roponin I Levels for Clinical Outcomes
nd Prognosis of Acute Chest Pain Patients
ichael C. Kontos, MD,*†§ Rakesh Shah, MD,* Lucie M. Fritz, PHD,‡ F. Philip Anderson, PHD,‡
ames L. Tatum, MD,§ Joseph P. Ornato, MD,† Robert L. Jesse, MD, PHD*
ichmond, Virginia
OBJECTIVES We compared outcomes in patients with non–ST-segment elevation acute coronary syn-
dromes (ACS) according to the degree of cardiac troponin I (cTnI) elevation.
BACKGROUND Controlled trials of high-risk patients have found that troponin elevations identify an even
higher risk subset. It is unclear whether outcomes are similar among a lower risk,
heterogeneous patient group. Also, few studies have reported outcomes other than myocardial
infarction (MI) or death, based on the peak troponin value.
METHODS Consecutively, admitted patients without ST-segment elevation on the initial electrocardio-
gram underwent serial marker sampling using creatine kinase (CK), CK-MB fraction, and
cTnI. Patients were grouped according to peak cTnI: negative  no detectable cTnI; low 
peak greater than the lower limit of detectability but less than the optimal diagnostic value;
intermediate  peak greater than or equal to the optimal diagnostic value but less than the
manufacturer’s suggested upper reference limit (URL); and high peak greater than or equal
to the URL. Thirty-day outcomes included cardiac death, MI based on CK-MB, revascu-
larization, significant disease, and a reversible defect on stress testing. Six-month mortality
was also determined. Negative evaluations for ischemia included nonsignificant disease, no
reversible stress defect, and negative rest perfusion imaging.
RESULTS Of the 4,123 patients admitted, 893 (22%) had detectable cTnI values. Cardiac events and
positive test results at 30 days and 6-month mortality increased significantly with increasing
cTnI values. Negative evaluations for ischemia were significantly and inversely related to peak
cTnI values. Although adverse events were significantly more common in patients with a low
cTnI value than in those with negative cTnI, negative evaluations for ischemia were frequent.
CONCLUSIONS Increased cTnI values are associated with worse outcomes. Although low cTnI values are
associated with adverse events, they do not have the same implication as higher cTnI values, and
nonischemic evaluations are frequent. (J Am Coll Cardiol 2004;43:958–65) © 2004 by the
American College of Cardiology Foundationf
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Toth cardiac troponins T (cTnT) and I (cTnI) have a higher
ensitivity for detecting myocardial necrosis than do tradi-
ional cardiac markers (1,2). They also add significant
ncremental diagnostic and prognostic value to routine
linical and electrocardiographic (ECG) variables for iden-
ifying patients at risk of cardiac events (3,4). These ad-
antages led a joint committee of the European Society of
ardiology and American College of Cardiology (ESC/
CC) to recommend that patients who have detectable
ardiac troponin, as a result of myocardial ischemia, be
iagnosed as having acute myocardial infarction (MI) (5).
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cios, Cor Therapeutics, Millenium, Genentech, Aventis, Genentech, Merck and Co,
nc., Dade Behring, and DuPont.
Manuscript received May 20, 2003; revised manuscript received September 30,
w003, accepted October 6, 2003.Patients with troponin elevations appear to benefit pre-
erentially from antiplatelet (6–8) and antithrombotic treat-
ent (9), as well as early coronary angiography (2). As a
esult, these treatment strategies have been incorporated
nto recommendations for the treatment of patients with
on–ST-segment elevation acute coronary syndromes (ACS)
3,4). However, these recommendations were based primarily
n studies that evaluated outcomes in higher risk patients
nrolled in ACS trials. In addition, the definition of positive
roponin varies substantially among the studies (2,6,7,10–12).
herefore, the conclusions drawn are difficult to apply and may
ot be valid in lower risk patients, such as those undergoing an
valuation in the emergency department (ED), particularly
hose with lower troponin concentrations. In this study, we
ssessed outcomes based on different peak cTnI values in a
arge, consecutive group of patients admitted from the ED for
xclusion of myocardial ischemia.
ETHODS
his study was performed at a 600-bed, inner-city hospital
ith approximately 85,000 ED visits and 1,500 coronary
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March 17, 2004:958–65 Troponin I and Outcomesare unit (CCU) admissions per year. The chest pain
rotocol used at our institution has been described in detail
reviously (13). In brief, after the initial evaluation, patients
hought to be at high risk (those with ischemic ECG
hanges and those with known coronary disease experienc-
ng typical symptoms) are admitted directly to the CCU.
atients considered at low to moderate risk of ACS (e.g.,
bsence of ischemic ECG changes) undergo further risk
tratification using rest myocardial perfusion imaging (MPI)
13). Moderate-risk patients are admitted as observation
atients and undergo serial marker sampling to exclude MI.
ow-risk patients undergo rest MPI in the ED and are
ischarged and scheduled for outpatient stress testing if the
mages are either negative or unchanged from previous
tudies. Markers are not routinely measured in these pa-
ients. Patients with positive MPI are considered high risk
nd admitted for MI exclusion.
A total of 4,567 consecutive patients were admitted to the
CU from June 1996 through March 2000. For patients with
ultiple admissions during each study period, only the first
dmission was included in the analysis. Patients with ST-
egment elevation who met criteria for fibrinolytic therapy (n
230) or did not have an 8-h cTnI (124 for assay 1; 101 for
ssay 2) were excluded, leaving 4,123 patients who formed the
tudy cohort. This study was approved by the Office of
esearch Subjects Protection for the Conduct of Human
esearch.
arkers. All patients underwent serial testing for creatine
inase (CK) and CK-MB by mass assay at 0, 3, 6, and 8 h
nd cTnI at 0 and 8 h after presentation. Patients who had
ositive markers or recurrent or continuing symptoms had
ampling continued at 6- to 8-h intervals until a peak value
as reached or a diagnosis was made. The peak cTnI value
uring the first 24 h was used for analysis.
Centrifuged plasma was filtered before CK-MB and
TnI analyses. Two different diagnostic assays for CK-MB
nd cTnI were used. From June 1996 to May 1998, the
pus Magnum Analyzer (Behring Diagnostics, Boston,
assachusetts) was used. The lower limit of detectability
Abbreviations and Acronyms
ACS  acute coronary syndromes
CCU  coronary care unit
CI  confidence interval
CK  creatine kinase
cTnI  cardiac troponin I
cTnT  cardiac troponin T
CV  coefficient of variation
ED  emergency department
ESC/ACC  European Society of Cardiology/
American College of Cardiology
LLD  lower limit of detectability
MI  myocardial infarction
MPI  myocardial perfusion imaging
URL  upper reference limitLLD) for this assay was 0.5 ng/ml, and the suggested diagnostic value for MI (upper reference limit [URL]) was
.5 ng/ml (14). The 99th percentile for patients without
oronary disease was 0.5 ng/ml. The coefficients of vari-
tion (CV) reported by the manufacturer were 12% and 5%
or cTnI values of 3.0 and 19 ng/ml, respectively. The CV
alues for lower cTnI values were not available. Outcomes
or these patients have been reported in detail previously
15). The current study represents expansion of outcomes
ssessed, as well as analysis using different cTnI diagnostic
alues from a previous study (15). From May 1998 to April
000, cTnI was analyzed using the Bayer assay (Bayer
orp., Tarrytown, New York). The LLD for this assay was
.1 ng/ml, and the suggested diagnostic value for MI was
.9 mg/ml (10). The 99th percentile determined in 200
atients without evidence of coronary disease was 0.1
g/ml. The CV for this assay at our institution was 15%
t a cTnI concentration of 0.3 ng/ml. For CK-MB, an URL
f 8.0 ng/ml was used for both assays.
For each of the two assays, we chose an optimal diagnos-
ic value for cTnI (Opus, 1.0 ng/ml; Bayer, 0.3 ng/ml),
hich improved specificity without affecting sensitivity,
ompared with the reference standard CK-MB MI defini-
ion. Sensitivity (96% vs. 97%) and specificity (93% vs. 92%)
t the optimal diagnostic value were similar and not statis-
ically different for the two assays. In addition, they were
quivalent to the recent ESC/ACC definition of MI.
atients were then separated into four groups according to
eak cTnI values: 1) negative  no detectable cTnI; 2) low
peak cTnI values greater than or equal to the LLD and
ess than the optimal diagnostic value; 3) intermediate 
eak cTnI values greater than or equal to the optimal
iagnostic value but less than the URL; and 4) high  peak
TnI values greater than or equal to the URL.
The results from the two assays were subsequently com-
ined because the areas under the receiver-operating char-
cteristics curve for the two assays (Opus assay, 0.977 
.04; Bayer assay, 0.971  0.04) were comparable and not
ignificantly different, indicating similar diagnostic test per-
ormance. In addition, there was no significant difference
etween the two groups in the baseline characteristics
ssociated with adverse cardiac outcomes and test results in
CS patients (Table 1).
utcomes. Patient outcomes occurring within 30 days of
dmission were assessed. When a patient experienced more
han one cardiac event, only one was considered, based on
he following order: cardiac death, criteria for MI at the
ime of admission, late CK-MB MI (24 h but within 30
ays), revascularization, significant coronary disease, and a
eversible defect on stress imaging. Negative evaluations for
schemia were assessed in a similar fashion and included
onsignificant disease on angiography, a normal or fixed
efect on stress MPI, and negative rest MPI during the ED
valuation. Cardiac death was defined as death due to MI,
oronary artery disease, or arrhythmia. In addition, six-
onth cardiac mortality was also assessed. Mortality wasetermined using chart review, scripted phone interviews,
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Troponin I and Outcomes March 17, 2004:958–65nd death registry data from the Virginia Division of Health
tatistics and the Social Security Death Index. The
efinition of CK-MB MI was an elevation of CK-MB
8.0 ng/ml, with a relative index 4.0 (CK-MB 
00/total CK), in association with a characteristic marker
ise and fall. Significant coronary disease was defined as
60% left main stenosis and 70% stenosis in a major
oronary artery, its branches, or a bypass graft supplying
yocardium at ischemic risk. Stress testing was performed
sing symptom-limited exercise or pharmacologic stress with
ingle-photon emission computed tomographic MPI and was
onsidered abnormal if there was a reversible defect. Rest MPI
as considered positive if there was a perfusion defect in
onjunction with abnormal wall motion or thickening (13). An
schemic ECG was defined as transient ST-segment elevation,
T-segment depression1 mm, or ischemic T-wave inversion
symmetrical T-wave inverted 2 mm).
tatistical analysis. Results were compared using the Stu-
ent t test for continuous variables and chi-square analysis for
ichotomous variables. A value of p  0.05 was considered
ignificant in most cases. When differences in cardiac outcomes
ere compared among the different cTnI groups, a value p 
.017 was required to correct for multiple comparisons. Car-
iac mortality was shown using the Kaplan-Meier method,
ith comparisons made using the log-rank test. Significance of
he trend toward an increasing incidence of adverse outcomes
nd a decreasing incidence of negative ischemic evaluations
as assessed using linear regression analysis. A Cox regression
odel was used to model the hazard of six-month cardiac
ortality as a function of cTnI positivity. The Wald test was
sed to test for all pairwise difference in hazard rates. The
onferroni correction was used for multiple testing. Statistical
nalyses were performed using SAS version 8.2 (Cary, North
arolina).
ESULTS
he characteristics and demographic variables of the 4,123
Table 1. Demographics and Risk Factors for t
All Patients
(n  4,123)
Age (yrs) 58  14 (58)
Age 65 yrs 1,312 (32%)
Male 2,038 (49%)
Hypertension 2,709 (66%)
Diabetes 1,308 (32%)
Tobacco use 1,757 (43%)
Total risk factors 2.1  1.2 (2)
Previous revascularization 1,039 (25%)
Previous bypass surgery 528 (13%)
Previous angioplasty 725 (18%)
Prior MI 600 (15%)
CK-MB MI 341 (8.4%)
Ischemic ECG changes 493 (12%)
There were no significant differences between variables in the
or number (%) of subjects.
CK-MB  creatine kinase-MB; ECG  electrocardiogratients are shown in Table 1. A total of 346 patients (8.4%) cad CK-MB MI. Of the 893 patients (22%) who had
etectable cTnI values, 425 (10%) had cTnI values greater
han the URL (high cTnI), 198 (4.8%) had cTnI values less
han the URL but greater than or equal to the optimal
iagnostic value (intermediate cTnI), and 270 (6.5%) had
TnI values less than the optimal diagnostic value but
reater than the LLD (low cTnI). Serial testing made a
ifference in classifying these patients, as the initial cTnI
ften did not reflect the final classification. Among the low
TnI group, 45% had negative cTnI initially. Similarly, 49%
f patients in the intermediate cTnI group had initial cTnI
alues that were negative (29%) or low (20%), and 52% of
hose who had high cTnI values had initial values that were
egative (29%), low (13%), or intermediate (9%). Therefore,
f only the initial cTnI were used, 50% of the patients with
etectable cTnI values would have been misclassified.
Thirty-day and six-month follow-up was complete in
2% and 96%, respectively. Patients who did not have
ollow-up were significantly less likely to have cTnI eleva-
ions and revascularization, were younger, had fewer risk
actors for coronary disease, and were more likely to have an
valuation negative for ischemia. Additional diagnostic
esting was performed within 30 days of admission in 73%
f patients (n  3,020). A total of 1,508 patients (37%)
nderwent coronary angiography, with 579 (14%) undergo-
ng revascularization. Stress MPI was performed in 1,116
atients (27%) who did not undergo coronary angiography,
nd 396 patients (9.6%) had negative rest MPI during the
nitial ED evaluation but did not undergo further diagnostic
esting, other than serial marker sampling. At least one end
oint (cardiac death or CK-MB MI, or additional diagnos-
ic testing) was present in 76%, 69%, 67%, and 92% of
atients who had negative, low, intermediate, or high peak
TnI values, respectively. The distribution of test results
ased on peak cTnI values are shown in Table 2.
Six-month cardiac mortality is shown in Figure 1. There
as a highly significant (p  0.0001) stepwise increase in
wo Populations
Assay 1
(n  1,943)
Assay 2
(n  2,180)
58  14 (58) 58  14 (58)
630 (12%) 682 (31%)
946 (49%) 1,092 (50%)
1,271 (65%) 1,438 (66%)
615 (32%) 693 (32%)
809 (42%) 948 (44%)
2.1  1.2 (2) 2.2  1.2 (2)
464 (24%) 531 (24%)
255 (13%) 273 (13%)
340 (18%) 385 (18%)
286 (15%) 315 (14%)
176 (9.1%) 170 (7.8%)
215 (11%) 278 (13%)
roups. Data are presented as the mean value  SD (median)
I  myocardial infarction.he T
two gardiac mortality as peak cTnI increased. After correcting
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March 17, 2004:958–65 Troponin I and Outcomesor multiple comparisons, mortality was significantly higher
n all cTnI groups, including the low cTnI group, compared
ith the negative cTnI group (p  0.01). In addition,
ortality was significantly different between the low and
igh cTnI groups. Differences between the low and inter-
ediate cTnI groups and the intermediate and high cTnI
roups were not statistically significant. Compared with the
egative cTnI group, the hazard ratio for the low cTnI
roup was 2.5 (95% confidence interval [CI] 1.4 to 4.4), 3.9
or the intermediate cTnI group (95% CI 2.3 to 6.8), and
.1 for the high cTnI group (95% CI 4.2 to 8.7).
Thirty-day outcomes based on peak cTnI values are
hown in Figure 2. In each of the outcome categories, the
rend toward an increasing incidence of ischemic outcomes
ith increasing peak cTnI was highly significant. Figure 2
lso shows the differences between each cTnI group. Only a
mall minority of patients who had low or negative cTnI
alues met CK-MB criteria for MI. In contrast, the majority
f patients with high cTnI values had CK-MB MI. The
esults were essentially unchanged after excluding patients
ho had CK-MB MI at the time of admission (Fig. 3).
The incidence of evaluations that were negative for
schemia showed an inverse relation to peak cTnI values,
ecreasing as peak cTnI values increased. An evaluation that
able 2. Cardiac Outcomes and Test Results Based on Peak Car
Death MI Revasc.
one (n  3,229) 22 (0.7%) 8 (0.2%) 306 (9.5%)
ow cTnI (n  270) 6 (2.2%) 3 (1.1%) 42 (16%)
ntermediate cTnI (n  198) 6 (3.0%) 29 (15%) 49 (25%)
igh cTnI (n  426) 30 (7.0%) 306 (72%) 186 (44%)
patient could have more than one event or test result. Data are expressed as the n
cTnI  cardiac troponin I; MI  myocardial infarction; MPI  myocardial perf
)  negative.
igure 1. Kaplan-Meier curves of six-month cardiac mortality for the diffe
ncreased cTnI was highly significant (p  0.001). In addition, mortality w
ntermediate (inter), and high cTnI groups.as negative for ischemia (CK-MB MI excluded and either
onsignificant coronary disease, no reversible stress defect,
r negative rest MPI) was found in 54% of those without
TnI elevations, 42% of those with low cTnI values (p 
.001 vs. negative cTnI group), 22% of those with interme-
iate values (p  0.001 vs. low cTnI group), and only 8.7%
f those with high cTnI values.
Because the distinction between negative cTnI and low
TnI values was of particular interest, the two groups were
urther analyzed. When the two groups were compared, the
ifferences in six-month cardiac mortality was significant (p
0.02) (Fig. 1). Events at 30 days (including the combi-
ations of death and MI; death, MI, and revascularization;
nd death, MI, and significant disease) also differed signif-
cantly (Figs. 2 and 3). When patients in the low cTnI group
ho had an ischemic evaluation were compared with those
ho did not, the only variables different were the presence
f an ischemic ECG (22% vs. 10%, p  0.05) and ECG
vidence of previous MI (20% vs. 9%, p  0.05).
When outcome and test results were analyzed individu-
lly, a similar gradient appeared, with the incidence of
eath, MI, revascularization, and significant disease increas-
ng as cTnI values increased. Also, the incidence of negative
ardiac evaluations decreased as peak cTnI values increased
Troponin I Value
Sig Dz () Stress Non-Sig Dz () Stress () MPI
41 (17%) 298 (9.2%) 488 (15%) 967 (30%) 353 (11%)
59 (22%) 19 (7.0%) 37 (14%) 56 (21%) 29 (11%)
67 (34%) 6 (3.0%) 20 (10%) 22 (11%) 9 (4.5%)
64 (62%) 14 (3.3%) 31 (7.3%) 15 (3.5%) 5 (1.2%)
r (%) of subjects.
imaging; Revasc.  revascularization; Sig Dz  significant disease; ()  positive;
ardiac troponin I (cTnI) values. The trend toward increased mortality and
gnificantly different (p  0.01) between the negative (neg) cTnI and low,diac
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Troponin I and Outcomes March 17, 2004:958–65Table 2). The only exception was a positive stress test
esult, which was likely due to coronary angiography being
erformed as the preferred initial evaluation.
ISCUSSION
n this large study of ED chest pain patients without
T-segment elevation on the initial ECG, we found a
ignificant incremental increase in cardiac events and posi-
ive test results as the peak cTnI value increased. Low peak
TnI values predicted cardiac events, but negative evalua-
igure 2. Positive outcomes based on peak cardiac troponin I (cTnI) values.
as highly significant (p  0.001). *p  0.001. #p  0.02. Open bars 
ars  intermediate troponin I; diagonally striped bars  high troponin I
isease.
igure 3. Positive outcomes based on peak cardiac troponin I (cTnI) value
dmission as an end point. The trend toward an increased number of event
pen bars  no troponin I; vertically striped bars  low troponin I; ho
igh troponin I. Revasc  revascularization; Sig Dz  significant disease.ions for ischemia were also common. Importantly, these
elationships persisted after excluding CK-MB MI at the
ime of admission as an end point.
We separated patients into four groups based on their
eak cTnI value, using the URL, LLD, and optimal
iagnostic value as decision limits. The first two were
hosen because they are the most commonly used values in
esearch studies and clinical practice (2,10,16,17). The
hird—the optimal diagnostic value—was chosen using
eceiver operating characteristic curve analysis, which allows
trend toward an increased number of events for increasing peak cTnI values
oponin I; vertically striped bars  low troponin I; horizontally striped
 myocardial infarction; Revasc  revascularization; Sig Dz  significant
r excluding creatine kinase-MB myocardial infarction (MI) at the time of
increasing peak cTnI values was highly significant (p  0.001). *p  0.02.
tally striped bars  intermediate troponin I; diagonally striped bars The
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March 17, 2004:958–65 Troponin I and Outcomesore appropriate selection of a diagnostic value through
ptimization of sensitivity and specificity (18). This value
as similar to the one proposed by the ESC/ACC (10%
V) (5).
on-MI end points. The majority of reports analyzing
utcomes based on troponin positivity used only the “hard”
nd points of MI and death. However, these outcomes
ccur in only a minority of patients; therefore, this approach
rovides only a limited assessment of the diagnostic ability
f troponin. It also fails to identify patients in whom
utcomes may be impacted by subsequent treatment, such
s revascularization. Studies that have reported other out-
omes, such as stress testing (19,20) or coronary angiogra-
hy (21), typically included too few patients to analyze
utcomes based on different troponin levels. Only two
tudies did include sufficient numbers, allowing stratifica-
ion by troponin concentration (22,23). Although per-
ormed in a population of predominately high-risk ACS
atients, both studies reported results similar to ours:
ncreasing troponin values were associated with a higher
revalence of positive stress tests, significant coronary dis-
ase, and revascularization procedures (22,23). Our results
xtend this finding to lower risk patients. In addition, we
ound that negative ischemic evaluations increased with
ecreasing cTnI values.
ow cTnI and outcomes. Because cardiac troponin is not
ormally found in the blood, small amounts of damage,
hich may not meet traditional criteria for MI, can be
etected. Studies performed in high-risk ACS patients did
ot find any concentration of detectable troponin that was
ot associated with increased risk (1,2,5,24). This observa-
ion led to the current recommendation that, in the proper
etting, any detectable troponin should be considered
athologic and indicative of MI (5). In addition to identi-
ying troponin as the preferred diagnostic marker, the
ecommendations also specified that the diagnostic cut-off
alue should be 99th percentile. The LLD for the two
ssays used in the present study met this criteria, as they
ere undetectable in large control groups.
Several studies that used the LLD for cTnI (2,25) and
TnT (2) observed that the presence of these minor eleva-
ions was associated with a significantly higher cardiac event
ate, compared with the absence of detectable troponin. In
ontrast, other studies performed in lower risk patient
opulations found no such difference (16,26–28). This
iscrepancy can be attributed to two factors: patient risk and
ohort size. Unlike patients in most ACS trials which have
high prevalence of MI, most ED patients have a low
verall risk. Greater numbers of patients are therefore
equired to demonstrate a significant difference in outcomes.
he large number of patients in the current study allowed us
o demonstrate a stepwise increase in events with increasing
TnI values, confirming that even small cTnI elevations
ave prognostic significance.
However, evaluations that were negative for ischemiaere common in patients with low cTnI values. One txplanation is that previous treatment and preprocedural
elays resulted in thrombus resolution by the time angiog-
aphy was performed (29). Positive cTnI values in patients
ith negative imaging could be related to the relative
nsensitivity of MPI, as approximately 3% to 5% of myo-
ardium must be ischemic for detection (30). Another
ossible mechanism is the release of small amounts of
roponin resulting from global ischemia and patchy necrosis,
uch as during a hypertensive crisis or severe heart failure,
ather than through prolonged ischemia and infarction from
picardial coronary artery disease. However, the high num-
er of patients with low cTnI elevations who did not have
vents suggests that most discrepancies represent analytical
alse-positive results due to the assays themselves, rather
han necrosis.
Troponin I values just above the LLD have been a source
f considerable diagnostic confusion. In contrast to ACS
rials, only a minority of ED patients with chest pain have
iagnostic ECG changes. Because atypical presentations are
requent, the presence of troponin elevations is often the
rimary, if not only, criterion used to diagnose these
atients as having MI. Spurious elevations have been
requent enough in some studies (31–33) so that the term
troponinosis” (33) has been coined to describe them.
A high prevalence of analytical false-positive results has
mportant implications for the treatment of chest pain
atients. Troponin-positive patients appear to benefit pre-
erentially from more intensive antiplatelet and antithrom-
otic therapy (6,7,12,16,34), as well as early coronary
ngiography with revascularization, when appropriate
2,12). Recommendations for the treatment of patients with
on–ST-segment elevation ACS now use the detection of
roponin to guide diagnostic and therapeutic measures (3,4).
iven the high frequency of negative subsequent evalua-
ions in chest pain patients with low troponin elevations,
uch intensive treatment may not be warranted in all
atients (16,35). Rather, treatment decisions should be
ased on clinical variables indicative of high risk, such as an
schemic ECG or previous MI.
The high frequency of analytical false-positive troponin
alues near the LLD led to the ESC/ACC recommendation
f10% CV at the diagnostic value (5). Almost none of the
urrently available cTnI assays (36–38) or the current cTnT
ssay (39) are able to achieve this. Thus, fulfilling this
equirement will require a higher diagnostic value, often two
o three times the LLD. Values that fall between the LLD
nd the diagnostic value are therefore indeterminate and are
ot to be considered diagnostic of MI.
It is unclear what these indeterminate troponin values
hould be called. Based on the ESC/ACC definition, they
ould be considered negative. However, our data, as well as
hose of others (2), indicate that these lower cTnI values
ave prognostic value, so disregarding them is not appro-
riate. Our data suggest that until assays meeting the
riteria specified by the ESC/ACC are available, the use of
wo decision limits, as suggested by the National Academy
o
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ould be diagnosed if the troponin value exceeded the
iagnostic limit, whereas lower values would be considered
quivocal, with further clinical correlation and evaluation
equired.
tudy limitations. Although the current study is observa-
ional, it has several advantages over many previous studies
n which troponin analyses were reported as substudies of
ontrolled clinical trials. In most multicenter trials, sampling
as performed at only one time point, reducing accuracy. In
ontrast, we performed serial sampling in all patients. The
respecified inclusion and exclusion criteria used in multi-
enter trials frequently lead to high-risk, relatively homo-
eneous populations (1,6–12) in which women and the
lderly are under-represented (17). Assessing a test’s perfor-
ance in only a high-risk population results in substantial
ias, thus limiting the ability to generalize the results.
herefore, studies such as ours are important to comple-
ent the information obtained from randomized, clinical
rials. Although this was a single-center study, the patient
haracteristics and outcomes, including the proportion of
atients who had CK-MB MI (25,28,41,42) and troponin
levations without CK-MB MI (25,27,28,42), were similar
o those reported in both single- and multicenter studies,
ndicating that these results should be generalizable to other
ites, as long as the definition of troponin positivity is
onsistent with the recent consensus recommendations (5).
Not all patients underwent diagnostic testing beyond
erial marker analysis. This reflects actual clinical practice in
hich individual patient variables and clinical judgment
ltimately determine what, if any, additional testing is
ecessary. However, the trend toward increased events as
TnI values increased was consistent across the spectrum of
utcome events. Also, physicians were not blinded to the
TnI values; therefore, further care was based in part on
hese results. Although clinical trials blind physicians to
roponin values, myocardial markers, including cTnI, are
outinely assessed in all patients admitted to most U.S.
ospitals (43). The range of diagnostic testing performed in
atients with and without cTnI elevations suggests that the
ecisions were based on the entire clinical presentation
ather than the cTnI results alone. We used cardiac rather
han all-cause mortality as an end point. In contrast to
linical trials, in which the majority of patients have a high
revalence of coronary disease, many of the patients in-
luded in the current study had a nonischemic cause for
heir chest pain, which would have increased the overall
ortality in the lower risk patients. Although follow-up was
ot complete, it was comparable to previous studies, and
atients without follow-up were at lower risk. Our use of
he Virginia Death Registry, as well as the Social Security
eath Index, which has been demonstrated to have a high
pecificity (44), further supports the veracity of our conclu-
ions.
onclusions. Cardiac troponin I elevations are associated
ith an increased adverse event rate, although low cTnIalues are frequently associated with a high rate of negative
valuations for ischemia. Therefore, the degree of troponin
levation, as well as clinical variables such as previous MI
nd an ischemic ECG, should be considered when deciding
reatment.
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